How to Optimize Patient Selection for Multiple Myeloma Therapies: With Binod Dhakal, MD; and Muhamed Baljevic, MD

In today’s episode, we had the pleasure of speaking with Binod Dhakal, MD, and Muhamed Baljevic, MD, about updates regarding patient identification for optimal multiple myeloma treatment. Dr Dhakal is an associate professor of medicine in the Division of Hematology at the Medical College of Wisconsin in Milwaukee. Dr Baljevic is an associate professor of medicine in the Division of Hematology Oncology, director of Plasma Cell Disorders Research, director of the Vanderbilt Amyloidosis Multidisciplinary Program, co-chair of the Protocol Review and Monitoring System, and disease team lead for plasma cell dyscrasias and lymphomas at the Vanderbilt-Ingram Cancer Center, part of the Vanderbilt University Medical Center in Nashville, Tennessee.

In our exclusive interview, Drs Dhakal and Baljevic discussed first- and subsequent-line treatment options for patients with multiple myeloma, treatment options beyond CAR T-cell therapy for unfit patients, and ongoing research that may expand the myeloma treatment paradigm in the future.